Data Foundry

Drug recalls 2016

Cisatracurium Besylate Injection — Class II drug recall D-0819-2016

Terminated recall by Fresenius Kabi USA, LLC, reported 2016-04-20, distributed nationwide. Incorrect/ Undeclared Excipient: Firm is recalling product due to an incorrect statement of Preservative free

Recall numberD-0819-2016
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmFresenius Kabi USA, LLC, Lake Zurich, IL, United States
Recall initiated2016-04-05
Classified2016-04-12
Reported by FDA2016-04-20
Terminated2017-04-11
DistributedNationwide (US)
Quantity94,560 vials
Reason classesundeclared allergen, labeling
NDC63323-0416, 63323-0416-01, 63323-0416-05, 63323-0417, 63323-0417-01, 63323-0417-10, 63323-0418, 63323-0418-01, 63323-0418-20
Lot numbers6010157
Expiration dates2017-01

Product

Cisatracurium Besylate Injection, 20 mg per 10 mL (2 mg per mL), For intravenous injection, 10 mL Multiple Dose Vial, Rx only, Fresenius Kabi USA, LLC Lake Zurich, IL 60047, NDC 63323-417-10

Reason for recall

Incorrect/ Undeclared Excipient: Firm is recalling product due to an incorrect statement of Preservative free on the individual carton label. The vial label and outer carton label contain the correct statement of 0.9% benzyl alcohol added as a preservative.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0819-2016. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.